Invega Approval History
- FDA approved: Yes (First approved December 19th, 2006)
- Brand name: Invega
- Generic name: paliperidone
- Company: Janssen, L.P.
- Treatment for: Schizophrenia
Invega (paliperidone) is a once-daily oral atypical antipsychotic indicated for the acute and maintenance treatment of schizophrenia, and the acute treatment of schizoaffective disorder. Invega Sustenna is an extended-release injectable formulation of paliperidone administered once-monthly for the acute and maintenance treatment of schizophrenia.
FDA Approval History for Invega
|Apr 11, 2011|| Invega Approved as Treatment for Schizophrenia in Adolescents|
|Aug 6, 2009|| Invega Approved as the First and Only Treatment for Schizoaffective Disorder|
|Aug 3, 2009|| FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia|
|Feb 6, 2009||Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and Invega|
|Aug 27, 2008||FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia|
|Oct 29, 2007||Elan Announces the Johnson & Johnson Pharmaceutical Research
& Development Submission of a New Drug Application to the FDA
for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal
|Apr 27, 2007|| FDA Approves Invega for Long-Term Maintenance Treatment of
|Dec 21, 2006|| Invega Approved By FDA as New Treatment for Schizophrenia|
|Nov 10, 2006||Janssen, L.P. Selects Invega (paliperidone) Extended Release Tablets as Brand Name for Its Investigational Atypical Antipsychotic|
|Sep 29, 2006||FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia|
|Nov 30, 2005||New Drug Application Submitted for Paliperidone - a Potential New Treatment for Schizophrenia|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.